Listed

TherapeuticsMD, Inc.: Form 10-Q for the period ended Jun 30, 2013

Filed with the SEC on Aug 7, 2013 and accepted by EDGAR at Aug 7, 2013, 06:07 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-04-01 to 2013-06-30$2.1mus-gaap:SalesRevenueNet
Revenue6 months2013-01-01 to 2013-06-30$3.6mus-gaap:SalesRevenueNet
Cost of revenue3 months2013-04-01 to 2013-06-30$463.6kus-gaap:CostOfGoodsSold
Cost of revenue6 months2013-01-01 to 2013-06-30$844.0kus-gaap:CostOfGoodsSold
Gross profit3 months2013-04-01 to 2013-06-30$1.6mus-gaap:GrossProfit
Gross profit6 months2013-01-01 to 2013-06-30$2.8mus-gaap:GrossProfit
Research and development3 months2013-04-01 to 2013-06-30$1.7mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2013-01-01 to 2013-06-30$3.3mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2013-04-01 to 2013-06-30$5.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2013-01-01 to 2013-06-30$10.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2013-04-01 to 2013-06-30−$5.6mus-gaap:OperatingIncomeLoss
Operating income6 months2013-01-01 to 2013-06-30−$10.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2013-04-01 to 2013-06-30$150us-gaap:InterestExpense
Interest expense6 months2013-01-01 to 2013-06-30$1.2mus-gaap:InterestExpense
Net income3 months2013-04-01 to 2013-06-30−$6.0mus-gaap:NetIncomeLoss
Net income6 months2013-01-01 to 2013-06-30−$12.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2013-04-01 to 2013-06-30−$0.05us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2013-01-01 to 2013-06-30−$0.11us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2013-01-01 to 2013-06-30−$10.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2013-01-01 to 2013-06-30$22.9kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2013-06-30$34.4mus-gaap:Cash
Current assetsAt period end2013-06-30$40.5mus-gaap:AssetsCurrent
Total assetsAt period end2013-06-30$43.1mus-gaap:Assets
Current liabilitiesAt period end2013-06-30$4.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-06-30$4.6mus-gaap:Liabilities
Shareholders' equityAt period end2013-06-30$38.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001387131-13-002760. Last ingested by Listed: Nov 14, 2026, 19:24 ET. Listed shows no prices and gives no investment advice.